Clinical Trial Update: GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating Galactose Single Point (GSP) as a novel indicator of residual liver function in patients with fatty liver disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver Disease
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Galactose Single Point (GSP) (Galactose Single Point)

Snippet

Sponsor: National Defense Medical Center, Taiwan | Conditions: Galactose Single Point (GSP), Residual Liver Function | Phase 1, Phase 2 | Status: COMPLETED